# ğŸ« Lung Fibrosis scRNA-seq Analysis (GSE141259) - Day 1

**Date:** 16-1-2026
**Project:** Lung Regeneration & Fibrosis (Bleomycin Model)  
**Author:** Nora

---

## ğŸ“ Summary (æ‘˜è¦)
This document records the progress of Day 1 analysis using the `GSE141259` dataset. The workflow covers raw data preprocessing, quality control, integration of author-provided annotations, and preliminary investigation of cell type dynamics during disease progression (PBS vs. Bleomycin time course).
æœ¬æ–‡æ¡£è®°å½•äº†åŸºäº `GSE141259` æ•°æ®é›†ç¬¬ä¸€å¤©çš„åˆ†æè¿›åº¦ã€‚å·¥ä½œæµç¨‹æ¶µç›–äº†åŸå§‹æ•°æ®é¢„å¤„ç†ã€è´¨é‡æ§åˆ¶ã€ä½œè€…æ³¨é‡Šä¿¡æ¯çš„æ•´åˆï¼Œä»¥åŠå¯¹ç–¾ç—…è¿›ç¨‹ï¼ˆPBS å¯¹ç…§ç»„ä¸åšæ¥éœ‰ç´ æŸä¼¤ç»„çš„æ—¶é—´åºåˆ—ï¼‰ä¸­ç»†èƒç±»å‹åŠ¨æ€çš„åˆæ­¥æ¢ç©¶ã€‚

---

## ğŸ“‚ Repository Structure (æ–‡ä»¶ç»“æ„)
* **`01_preprocessing_standard.R`**: Script for loading raw counts, QC, normalization, and metadata integration. (æ•°æ®åŠ è½½ã€è´¨æ§ã€æ ‡å‡†åŒ–åŠå…ƒæ•°æ®æ•´åˆè„šæœ¬)
* **`02_disease_comparison.R`**: Script for visualizing disease progression and validating marker genes. (ç–¾ç—…è¿›ç¨‹å¯è§†åŒ–åŠæ ‡å¿—ç‰©éªŒè¯è„šæœ¬)

---

## ğŸ› ï¸ Workflow & Achievements (å·¥ä½œæµç¨‹ä¸æˆæœ)

### Part 1: Data Preprocessing & Authorization (æ•°æ®é¢„å¤„ç†ä¸èº«ä»½ç¡®ç«‹)
* **Setup Seurat Object**: Successfully loaded the raw count matrix and initialized the Seurat object.
    * *æˆåŠŸåŠ è½½åŸå§‹è®¡æ•°çŸ©é˜µå¹¶åˆå§‹åŒ– Seurat å¯¹è±¡ã€‚*
* **Metadata Correction**: Corrected `orig.ident` from the auto-parsed "muc4169" to the project label "lianxixi".
    * *ä¿®æ­£å…ƒæ•°æ®ï¼šå°†è‡ªåŠ¨è§£æçš„ "muc4169" æ ‡ç­¾æ›´æ”¹ä¸ºé¡¹ç›®æ ‡ç­¾ "lianxixi"ã€‚*
* **Annotation Integration**: Loaded author-provided metadata (`GSE141259_WholeLung_cellinfo.csv`) and mapped cell types to the object. Handled `NA` values by assigning them as "Unknown".
    * *æ³¨é‡Šæ•´åˆï¼šåŠ è½½ä½œè€…æä¾›çš„å…ƒæ•°æ®æ–‡ä»¶ï¼Œå°†ç»†èƒç±»å‹æ˜ å°„åˆ°å¯¹è±¡ä¸­ï¼Œå¹¶å°†ç¼ºå¤±å€¼æ ‡è®°ä¸º "Unknown"ã€‚*
* **Dimensionality Reduction**: Performed standard normalization, scaling, PCA, and UMAP visualization.
    * *é™ç»´åˆ†æï¼šå®Œæˆæ ‡å‡†åŒ–çš„å½’ä¸€åŒ–ã€ç¼©æ”¾ã€PCA åŠ UMAP å¯è§†åŒ–ã€‚*

### Part 2: Disease Progression Analysis (ç–¾ç—…è¿›ç¨‹åˆ†æ)
* **Time-Course Grouping**: Identified 7 experimental groups: `PBS` (Control) and `d3, d7, d10, d14, d21, d28` (Bleomycin injury model).
    * *æ—¶é—´åºåˆ—åˆ†ç»„ï¼šè¯†åˆ«å‡º 7 ä¸ªå®éªŒç»„ï¼šPBSï¼ˆå¯¹ç…§ï¼‰åŠ d3-d28ï¼ˆåšæ¥éœ‰ç´ æŸä¼¤æ¨¡å‹ï¼‰ã€‚*
* **Dynamics Visualization**:
    * **Split UMAP**: Visualized cell shifts across time points. (*æ‹†åˆ† UMAP å›¾ï¼šå¯è§†åŒ–ç»†èƒéšæ—¶é—´çš„è¿ç§»ã€‚*)
    * **Trend Lines**: Plotted proportion changes for key cell types (AM, AT2, Krt8 ADI). (*æŠ˜çº¿å›¾ï¼šç»˜åˆ¶å…³é”®ç»†èƒç±»å‹çš„æ¯”ä¾‹å˜åŒ–è¶‹åŠ¿ã€‚*)
* **Marker Validation (Krt8 Story)**:
    * Verified `Sftpc` (AT2 marker) loss and `Krt8` (injury marker) emergence using **FeaturePlots**.
    * Confirmed `Krt8` expression specifically in the **Krt8 ADI** population (and normal airway cells) but NOT in healthy AT2 cells using **Violin Plots**.
    * *æ ‡å¿—ç‰©éªŒè¯ï¼šä½¿ç”¨ç‰¹å¾å›¾éªŒè¯äº† Sftpc çš„ä¸¢å¤±å’Œ Krt8 çš„å‡ºç°ï¼›ä½¿ç”¨å°æç´å›¾è¯å® Krt8 ç‰¹å¼‚æ€§è¡¨è¾¾äºæŸä¼¤åçš„ Krt8 ADI ç»†èƒç¾¤ï¼ˆåŠæ­£å¸¸æ°”ç®¡ç»†èƒï¼‰ï¼Œè€Œåœ¨å¥åº· AT2 ç»†èƒä¸­ä¸è¡¨è¾¾ã€‚*

---

## ğŸ“Š Key Findings (å…³é”®å‘ç°)
1.  **Cellular Shift**: A massive infiltration of macrophages and loss of AT2 cells were observed starting from day 3.
    * *ç»†èƒæ¼”å˜ï¼šä»ç¬¬ 3 å¤©å¼€å§‹è§‚å¯Ÿåˆ°å·¨å™¬ç»†èƒçš„å¤§é‡æµ¸æ¶¦å’Œ AT2 ç»†èƒçš„ä¸¢å¤±ã€‚*
2.  **Emergence of Krt8+ Cells**: A distinct `Krt8 ADI` population appears around d10-d14, coinciding with the peak of tissue injury.
    * *Krt8+ ç»†èƒçš„å‡ºç°ï¼šåœ¨ d10-d14ï¼ˆç»„ç»‡æŸä¼¤é«˜å³°æœŸï¼‰è§‚å¯Ÿåˆ°æ˜æ˜¾çš„ `Krt8 ADI` ç»†èƒç¾¤ã€‚*
3.  **Molecular Validation**: Confirmed that `Krt8 ADI` cells express high levels of *Krt8*, distinguishing them from healthy alveolar type 2 cells.
    * *åˆ†å­éªŒè¯ï¼šè¯å® `Krt8 ADI` ç»†èƒé«˜è¡¨è¾¾ *Krt8*ï¼Œå°†å…¶ä¸å¥åº·çš„è‚ºæ³¡äºŒå‹ç»†èƒåŒºåˆ†å¼€æ¥ã€‚*

---

## ğŸ”œ Next Steps (ä¸‹ä¸€æ­¥è®¡åˆ’)
* Perform Differential Expression Analysis (DEG) to identify genes driving the AT2-to-Krt8 transition.
    * *è¿›è¡Œå·®å¼‚è¡¨è¾¾åˆ†æ (DEG)ï¼Œå¯»æ‰¾é©±åŠ¨ AT2 å‘ Krt8 çŠ¶æ€è½¬å˜çš„å…³é”®åŸºå› ã€‚*

# ğŸ“‚ Work Log: Differential Expression Analysis (Krt8 ADI vs AT2)

**Date:** 2026-01-17  
**Author:** Nora  
**Script:** `03_scripts_runs/03_DEG_analysis.R`  
**Data Source:** GSE141259 (Mouse Lung Fibrosis Model)

---

## ğŸ¯ 1. Objective (åˆ†æç›®æ ‡)
To identify the molecular mechanisms driving the transition from healthy **AT2 cells** to the pathological **Krt8 ADI (Alveolar Differentiation Intermediate)** state. Specifically, to find Differentially Expressed Genes (DEGs) that characterize the "dedifferentiation" and "stress response" process.

## ğŸ› ï¸ 2. Workflow (åˆ†ææµç¨‹)
* **Data Loading:** Loaded the processed Seurat object (`lung_obj_final_analysis.rds`).
* **Set Identity:** Switched active identity to `cell.type`.
* **DEG Calculation:** Used `FindMarkers()` to compare `Krt8 ADI` (Group 1) vs `AT2 cells` (Group 2).
* **Visualization:** Generated Volcano Plots and UMAP Feature Plots to validate findings spatially.

## ğŸ§¬ 3. Key Biological Findings (ç”Ÿç‰©å­¦å‘ç°)

Through statistical analysis and spatial visualization, three key dimensions of the Krt8 ADI cell state were identified:

### A. Identity Switch (èº«ä»½äº’æ¢)
* **Loss of AT2 Marker:** `Sftpc` (Surfactant Protein C) was significantly **downregulated** (Log2FC â‰ˆ -2.5), indicating a loss of normal alveolar function (Dedifferentiation).
* **Gain of Injury Marker:** `Krt8` (Cytokeratin 8) was significantly **upregulated** (Log2FC â‰ˆ 3.16), serving as the distinct marker for this injury-associated cell state.

### B. Cellular Senescence (ç»†èƒè¡°è€/åœæ»)
* **Cycle Arrest:** `Cdkn1a` (p21) was highly upregulated (Top 10 upregulated genes). This suggests the cells are locked in a senescent state (cell cycle arrest) and unable to complete regeneration.

### C. Stress Response (å‹åŠ›åº”æ¿€)
* **High Stress Level:** `S100a6` and `Clu` (Clusterin) showed the most dramatic upregulation (Log2FC > 5). This reflects an intense survival response to tissue injury.

## ğŸ“Š 4. Visual Evidence (ç»“æœå›¾è¡¨)

| Plot Type | Filename | Description |
| :--- | :--- | :--- |
| **Volcano Plot** | `lianxixi_Volcano_Krt8_Final.png` | Highlights the global shift: Sftpc (Left/Down) vs Krt8/S100a6/Cdkn1a (Right/Up). |
| **Feature Plot** | `lianxixi_FeaturePlot_KeyGenes.png` | Spatial confirmation: `Krt8` expression is exclusive to the specific "bridge" population where `Sftpc` expression is lost, co-localizing perfectly with stress markers `S100a6` and `Cdkn1a`. |

## ğŸ“ 5. Conclusion (æ€»ç»“)
The analysis confirms that **Krt8 ADI cells** are not merely "different" AT2 cells, but a distinct, pathological cell state characterized by **dedifferentiation (loss of Sftpc)**, **senescence (Cdkn1a)**, and **high stress (S100a6)**. They represent a "stalled" regeneration intermediate in lung fibrosis.

---
*Created with R Seurat v4/v5*
